Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Triglycerides and risk for coronary artery disease.

McBride P.

Curr Atheroscler Rep. 2008 Oct;10(5):386-90. Review.

PMID:
18706279
2.
3.

Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome.

Grundy SM.

Am J Cardiol. 1998 Feb 26;81(4A):18B-25B. Review.

PMID:
9526809
4.

The triglyceride-high-density lipoprotein axis: an important target of therapy?

Szapary PO, Rader DJ.

Am Heart J. 2004 Aug;148(2):211-21. Review.

PMID:
15308990
5.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
6.

[Update: clinical lipidology].

Parhofer KG.

MMW Fortschr Med. 2013 Jul 25;155(13):49-52; quiz 53-4. Review. German. No abstract available.

PMID:
23964509
7.

Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?

Brinton EA.

Curr Atheroscler Rep. 2008 Feb;10(1):25-32. Review.

PMID:
18366982
8.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
9.

HDL and triglyceride as therapeutic targets.

Fruchart JC, Duriez P.

Curr Opin Lipidol. 2002 Dec;13(6):605-16. Review.

PMID:
12441884
10.

Hypertriglyceridemia as a possible independent risk factor for stroke.

Lisak M, Demarin V, Trkanjec Z, Basić-Kes V.

Acta Clin Croat. 2013 Dec;52(4):458-63. Review.

PMID:
24696996
12.

Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides.

Prenner SB, Mulvey CK, Ferguson JF, Rickels MR, Bhatt AB, Reilly MP.

Atherosclerosis. 2014 Oct;236(2):244-50. doi: 10.1016/j.atherosclerosis.2014.07.008. Epub 2014 Jul 22.

13.

Optimal therapy of low levels of high density lipoprotein-cholesterol.

Kashyap ML, Tavintharan S, Kamanna VS.

Am J Cardiovasc Drugs. 2003;3(1):53-65. Review.

PMID:
14727946
14.
15.
16.

New developments in the treatment of low high-density lipoprotein cholesterol.

Miller M.

Curr Atheroscler Rep. 1999 Jul;1(1):24-30. Review.

PMID:
11122688
17.

Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.

Posadas-Sánchez R, Posadas-Romero C, Mendoza-Pérez E, Caracas-Portilla NA, Cardoso-Saldaña G, Medina-Urrutia A, Jorge-Galarza E, Juárez-Rojas JG.

Am J Cardiol. 2012 Mar 1;109(5):636-41. doi: 10.1016/j.amjcard.2011.10.017. Epub 2011 Dec 9.

PMID:
22169129
18.

Recent developments in the treatment of hypertriglyceridemia.

Duriez P, Fruchart JC.

Curr Atheroscler Rep. 1999 Jul;1(1):31-7. Review.

PMID:
11122689
19.

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.

Toth PP.

Vasc Health Risk Manag. 2016 May 6;12:171-83. doi: 10.2147/VHRM.S104369. eCollection 2016. Review.

20.

High-density lipoprotein cholesterol and triglycerides in the statin era: a pending issue?

Paillard F.

Arch Cardiovasc Dis. 2009 Mar;102(3):165-7. doi: 10.1016/j.acvd.2008.12.001. Epub 2009 Feb 23. No abstract available.

Supplemental Content

Support Center